Physician profile
Robert Czyzewski
NPI 1558304782
$11,921.61
in general payments reported to CMS, 2019-2025
51 companies · $1,609 in 2025
The $1,609 reported for 2025 was more than what 87% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $437 · 2020: $2,274 · 2021: $1,857 · 2022: $1,258 · 2023: $2,374 · 2024: $2,114 · 2025: $1,609.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,026 · Education: $70.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,025.76 |
| Education | $70.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,960.82 | 2019-2025 | Farxiga, Lokelma |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $1,595.92 | 2020 | |
| Amgen INC. | $861.52 | 2020-2025 | Krystexxa, Repatha, Otezla |
| Dexcom, INC. | $585.01 | 2021-2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $575.08 | 2021-2025 | |
| Fresenius USA Marketing, INC. | $544.10 | 2019-2025 | Velphoro, Korsuva, Velphoro |
| Ani Pharmaceuticals, INC. | $454.82 | 2022-2025 | Purified Cortrophin Gel |
| Opko Pharmaceuticals, LLC | $408.33 | 2019-2023 | Rayaldee |
| Horizon Therapeutics Plc | $378.15 | 2019-2023 | Krystexxa |
| Vifor Pharma, INC. | $376.42 | 2020-2025 | Veltassa, Korsuva |
| Novartis Pharmaceuticals Corporation | $369.55 | 2019-2025 | |
| Lilly USA, LLC | $328.51 | 2019-2025 | Mounjaro, Jardiance, Trulicity |
| Baxter Healthcare | $300.23 | 2023 | Renal - Chronic |
| Otsuka America Pharmaceutical, INC. | $290.72 | 2019-2025 | Jynarque |
| Ardelyx, INC. | $284.89 | 2024-2025 | Ibsrela, Xphozah 30 Mg |
Show all 51 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $240.43 | 2023-2025 | Cologuard Collection Kit |
| Travere Therapeutics, INC. | $209.63 | 2023-2025 | |
| Glaxosmithkline, LLC. | $206.13 | 2021-2025 | Benlysta, Shingrix, Jesduvroq |
| Aurinia Pharma U.S., INC. | $176.45 | 2021-2024 | Lupkynis |
| Intuity Medical INC | $174.17 | 2023 | Pogo Automatic Blood Glucose Monitoring System |
| Mallinckrodt Hospital Products INC. | $168.04 | 2020-2025 | Acthar |
| Pfizer INC. | $155.25 | 2019-2024 | |
| Calliditas Therapeutics US INC. | $153.63 | 2022-2025 | Tarpeyo |
| Novo Nordisk INC | $146.82 | 2019-2025 | Ozempic, Wegovy |
| Abbvie INC. | $108.20 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $85.38 | 2020-2024 | Gardasil, Gardasil 9, Capvaxive |
| Corcept Therapeutics | $80.02 | 2024-2025 | Korlym |
| Vivus LLC | $63.05 | 2025 | Qsymia, Pancreaze |
| Akebia Therapeutics INC | $62.71 | 2019-2024 | Vafseo, Auryxia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.86 | 2019-2025 | Jardiance |
| Medtronic, INC. | $54.88 | 2021-2024 | Minimed 780g |
| Cvrx, INC. | $48.83 | 2024 | Barostim Neo System |
| Mallinckrodt Enterprises LLC | $42.20 | 2019 | |
| Abbott Laboratories | $37.36 | 2020-2024 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $36.50 | 2020-2021 | |
| Scpharmaceuticals INC. | $27.58 | 2025 | |
| Genentech USA, INC. | $27.41 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.63 | 2021-2022 | |
| Eisai INC. | $25.35 | 2021 | |
| Daiichi Sankyo INC. | $24.16 | 2021 | |
| Ascendis Pharma Endocrinology INC | $18.21 | 2025 | Yorvipath |
| Ultragenyx Pharmaceutical INC. | $17.30 | 2022 | |
| Lundbeck LLC | $16.07 | 2024 | Rexulti |
| Senseonics, Incorporated | $16.00 | 2019 | |
| Acerus Pharmaceuticals Corporation | $15.27 | 2022 | |
| Janssen Pharmaceuticals, INC | $15.00 | 2021 | |
| Phadia US INC. | $14.69 | 2023 | Immunocap |
| Alexion Pharmaceuticals, INC. | $14.58 | 2023 | Ultomiris |
| Insulet Corporation | $13.89 | 2019 | |
| Xeris Pharmaceuticals, INC. | $13.50 | 2024 | Recorlev |
| Teva Pharmaceuticals USA, INC. | $13.36 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Czyzewski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.